JMP Securities downgraded Seagen (SGEN) to Market Perform from Outperform without a price target following the proposed acquisition by Pfizer (PFE). Given the announcement and premium paid, the analyst does not expect any other bidders. The stock should trade approximately 10% higher as the completion of the acquisition gets closer, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen (NASDAQ:SGEN) Stock Gained 54% YTD. Can Its Momentum Continue?
- Seagen downgraded to Market Perform from Outperform at BMO Capital
- Needham downgrades Seagen, says competing bid unlikely
- Seagen downgraded to Hold from Buy at Needham
- Seagen downgraded to Market Perform from Strong Buy at Raymond James
